Skip to main content

University of Exeter Medical School

Dr Jinwei Zhang

Dr Jinwei Zhang

Senior Lecturer in Medicine





Hatherly Building, University of Exeter, Prince of Wales Road, Exeter, EX4 4PS, UK


Dr Jinwei Zhang has a very wide-ranging expertise, which makes him uniquely positioned to develop research at the interface between fields. He gained a solid theory and practice of training in the field of natural bioactive compounds, biochemistry and molecular biology, enzymology, pharmacology, drug discovery, signaling transduction and electrophysiology during his academic degrees and postdoc trainings. He studies signalling pathways that associated with human diseases, for examples, the neurodegenerative diseases including the LRRK2 associated Parkinson's disease (PD),  the amyloid precursor protein (APP) and Tau associated Alzheimer's disease (AD), neuropsychiatric disorders including epilepsy (WNK-SPAK-KCC2), High Blood Pressure & Kidney Disease (CUL3/KLHL3-WNK-SPAK-NCC) etc.. All these studies concern with elucidating and targeting ion transporters, kinases, protein-protein interactions using genetic mouse models, mass spectrometry, small molecules, electrophysiology, and CRISPR/Cas9 gene editing technologies to aid discovery and validation of new potential drug targets.


  • BSc, 2003, Fujian Normal University (Fuzhou City), China
  • MSc, 2007, Xiamen University (Xiamen City), and the Third Institute of Oceanography (Xiamen City), State Oceanic Administration, China
  • PhD, 2011, Newcastle University, Newcastle upon Tyne, UK
  • Fellow of the Higher Education Academy, 2019


Dr Jinwei Zhang obtained a BSc degree in Bioengineering from Fujian Normal University China in 2003. While there, he studied mutagenesis of Aspergillus niger for higher yield of multicomponent enzymes. He then obtained a MSc degree in Marine Microbial Biochemistry and Molecular Biology at The Third Institute of Oceanography (Xiamen), State Oceanic Administration China in 2007. While there, he studied marine ecology and cold-adapted enzymes from deep-sea bacteria. He then obtained a PhD degree in Biotechnology from Newcastle University UK in 2011. While there, he studied natural bioactive compounds and their applications in human health.

Since 2011, Jinwei pursued his interest in cellular signalling with a post-doctoral fellowship at the Medical Research Council (MRC)- Protein Phosphorylation and Ubiquitination Unit (PPU) in Dundee with Professor Dario Alessi OBE FRS, and with Professor Nathanael Gray at Harvard Medical School. While there, he studied LRRK2 associated Parkinson's disease, and contributed to the discovery of the most potent LRRK2 kinase inhibitors TAE684 and TTT3002, most selective LRRK2 inhibitor GSK2578215A, and the first brain penetrable LRRK2 inhibitors HG-10-102-01 and JH-II-127.

Since 2014, Jinwei's research established the CUL3/KLHL3-WNKs-SPAK/OSR1-cation chloride cotransporters (CCCs) signalling in cellular chloride homeostasis and cell volume regulation in collaboration with Professor Kristopher Kahle at Yale University School of Medicine. In 2017, Jinwei joined the Faculty of the University of Exeter Medical School, where his KCC2/ NKCC1 investigations can gain greater impact by integration with the clinical resources and basic science research at The Institute of Biomedical and Clinical Sciences.

Recent research in Zhang Laboratory has greatly improved our understanding of the function of Chloride ion transporters, e.g. NCC, NKCC2, NKCC1, KCC2 and KCC3, and their upstream regulatory mechanism by the WNK-SPAK/OSR1 signalling pathway in mammalian cells and tissues under physiological and pathological conditions (Cell Metabolism 2017; Nature Medicine 2017; Nature Communications 2017; eLife 2018; Neuron 2019; Science Signalling 2019a, Science Signalling 2019b; Nature Communications 2020;  Molecular Psychiatry 2021;  Stroke 2022; Genetics in Medicine 2022; Nature Communications 2023; and Cell 2023), and subsequently led to the development of a drug-like molecular ZT-1a (Patents granted in United States (US10995061B2 and US11414379B2), granted Canadian Patent (CA3115075A1), granted Australian Patent (AU2019351731A1), granted Chinese Patent(CN113365614A), granted  European Patent (EP3873439A1) and granted South African Patent (ZA202102261A), as a neuroprotective agent.  Brain swelling or cerebral edema after a stroke, hydrocephalus or epilepsy is a common and devastating problem for individuals and their families. This current discovery could address the urgent need for treatment that could provide an effective alternative to invasive surgery. This work has been featured by Science Magazine News, ScienceBlog News, EurekAlert, Drug Target Review News, Chinadaily, and other medias.

Research group links

Back to top


Research interests

Genetic and pharmacological modulation of the WNK-SPAK-KCC2/NKCC1 signalling pathway: implications for function and pathology in cortical networks

Homeostasis of the intracellular ionic milieu is essential for the proper functioning of all cells and a diverse group of cellular processes. The mechanisms responsible for the homeostasis of the intracellular Cl- concentration [Cl-]i, for example, significantly impacts the rate of fluid secretion or absorption across epithelia; how red blood cells counteract potentially damaging osmotic-induced cell swelling or shrinkage; and whether the GABA neurotransmitter excites or inhibits post-synaptic neurons.

The neuronal potassium-chloride co-transporter KCC2 is one of the molecules effectively controlling intracellular Cl- and adjusting the inhibitory strength of GABA. KCC2 hypofunction results in decreased inhibition and increased network hyperexcitability that underlies numerous neurological disorders including epilepsy, autism, post-surgical complication, neuropathic pain and neuropsychiatric disorders.

KCC2 activity is decreased in most diseases associated with GABAergic disinhibition. A positive modulator (i.e., “activator”) of KCC2 might be effective in reversing the effects of KCC2 downregulation and lowering [Cl–]i to restore GABAergic inhibition. 

The activity of KCC2 is critically controlled by phosphorylation of two highly conserved residues (KCC2 Thr906/Thr1007), our recent work discovered that it is WNK-regulated SPAK/OSR1 kinases that directly phosphorylate KCC2 at Thr1007 and Thr906, thereby leading to its inhibition (Biochem. J. 2014, Sci. Signal. 2015, Sci. Rep. 2016, Nat. Comm. 2017, eLife 2018, Sci. Sig. 2019a, Sci. Sig. 2019b, Nat. Comm. 2020, Molecular Psychiatry 2021,  Genetics in Medicine 2022, Nature Communications 2023, and Cell 2023). This has potential implications for the therapeutic modulation of neurological disorders by targeting of WNK-SPAK/OSR1 with kinase inhibitors, with a new strategy to enhance cellular chloride extrusion. 

Dr Zhang and his colleagues aim to study Cul3/KLHL3-WNK-SPAK signalling pathway and KCC2 mouse models involved in control of the KCC2 activity and downstream GABAergic neurotransmission during neuronal development under physiological conditions and in models of epilepsy and autism, and to develop small molecular compounds that suppress WNK-SPAK kinase signalling pathway and therefore to activate KCC2. Indeed, our recent developed drug-like molecular ZT-1a (Nature Communications 2020; Stroke 2022; Patents granted in United States (US10995061B2 and US11414379B2), granted Canadian Patent (CA3115075A1), granted Australian Patent (AU2019351731A1), granted Chinese Patent(CN113365614A), granted  European Patent (EP3873439A1) and granted South African Patent (ZA202102261A),  could potently activate KCC2 and inhibit NKCC1 by blocking the WNK-SPAK/OSR1 signalling.

Marine Microbial-Derived Molecules and Their Potential Medical and Cosmetic Applications

The marine environment is a vast, largely unexploited resource for acquiring a multitude of microbial communities with a number of unknown taxonomic groups and novel biosynthetic capabilities. Marine habitats provide unique conditions for microbial growth and secondary metabolite expressions that are not found in terrestrial ecosystems. The co-evolution of many marine macroorganisms, especially invertebrates, with these microorganisms often leads to a very close association or symbiotic relationship between the host organism and specific microbial species driven by natural products. The ocean basin floor is covered in sediments of different types and origins. Marine sediments are considered to be an incredibly rich source of microbial taxonomic diversity, including culturable and ‘unculturable’ microbes. For culturable microbes, we could either grow mixed strains as biofilms for certain purposes, e.g. electricity generation (Zhang et al., Environ. Sci. Technol. 2012), or isolate novel strains identified as new species (Zhang et al., J. Microbiol. Biotechnol, 2007; Zhang et al., Int. J. Syst. Evol., 2015), for cold active enzymes, or for bioactive compounds (Zhang et al. Marine Biotechnology, 2008; Zhang et al., World J. Microbiol. Biotechnol. 2011), e.g. Omega-3 polyunsaturated fatty acids (EPA and DHA) (Zhang et al. PLOS ONE, 2017).

Whereas, 'unculturable' microbial diversity presents a vast gene pool for biotechnological exploitation. In this context the secondary metabolites produced by the microbial species and their biosynthetic pathways represent a resource in the discovery of novel molecules or enzymes for a wide number of applications especially in the medical and cosmetic field. Sustainable use of these resources is a methodological challenge: new culture techniques in addition to culture-independent methods, such as PCR amplification from microbial community DNA (metagenome) and functional or sequence-based screening of metagenomic DNA libraries are proving useful for the exploitation of 'unculturable' microbes and their novel gene clusters responsible for biosynthetic pathways for new bioactive compounds and enzymes ((Zhang et al, Prog. Biochem. Biophys., 2006; Zhang et al., Marine Biotechnology, 2008).

In recent years, efforts to characterize marine microbial metagenomics and their associated compounds and enzymes have expanded significantly, but given the vastness of the marine environment and the different types of microbial habitats found there, this research is still in its infancy.

Zhang Laboratory also explores the marine microbial community dynamics, genome sequencing and gene editing technology, marine microbial-derived molecules and their potential medical and cosmetic applications (Zhang et al. Frontiers in Microbiology, 2021, 2023). The aim is to promote our understanding of marine-derived biomolecules and their applications.  An example of study, Staurosporine produced by marine-derived actinomycete Streptomyces roseoflavus, could potently inhibit WNK-SPAK/OSR1 signalling mediated phosphorylation of KCC2 at Thr906/1007 and NKCC1 Thr203/207/212 (Zhang et al. PLOS ONE 2020).

Research networks


Back to top

External Engagement and Impact


  • Above & Beyond Award (Excellent), the University of Exeter (2022)
  • Outstanding Contribution Award for his contributions to the development of the journal 'Journal of Exploratory Research in Pharmacology (2021)
  • Above & Beyond Award (rigour), the University of Exeter (2019)
  • Bursary Award, Parkinson's UK (2012)
  • Outstanding Young Scientist Award, American Oil Chemists Society (2010)
  • Travel Grant Award, European Section of the American Oil Chemists Society (2010)
  • Second-class Award of Publication, Journal 'Progress in Modern Biomedicine’ (2010)
  • BBSRC-Croda Dorothy Hodgkin Scholar, Newcastle University UK (2008-2011) 
  • Third-class Award of Publication, State Oceanic Administration, China (2008)
  • Outstanding Young Scientist Award, Chinese Enzyme Engineering Society (2005)
  • Fujian Normal University Scholarship Award (2009-2003)

Editorial responsibilities

Invited or ad hoc Reviewers for more than 200 manuscripts, for the following Journals

  1. Cell Metabolism (Cell press, IF 31.373)
  2. Chem (Cell press, IF 25.832)
  3. Heliyon (Cell press, IF 4.0)
  4. Medicinal Research Reviews (Wiley press, IF 14.06)
  5. Advanced Science (Wiley press, IF 15.1)
  6. Clinical and Translational Medicine (Wiley press, IF 10.6)
  7. Journal of Neuroscience Research (Wiley press, IF 4.4)
  8. Biochemical Journal (Portland press, IF 3.766)
  9. Expert Systems With Applications (Elsevier, IF 8.665)
  10. Biochemical Pharmacology (Elsevier, IF 5.858)
  11. Open Biology (Journal of the Royal Society, IF 7.129)
  12. Journal of Biological Chemistry (IF 5.486)
  13. Human Molecular Genetics (Oxford Academic, IF 5.3)
  14. Scientific Reports (IF 4.9)
  15. Biochemistry (IF 4.857)
  16. The Journal of Physiology (IF 6.228)
  17. Aging and Disease (IF 7.4)
  18. Microbial Biotechnology (IF 6.575)
  19. Journal Of Cellular and Molecular Medicine (IF 5.295)
  20. Frontiers in Immunology (IF 8.786)
  21. Frontiers in Pharmacology (IF 5.988)
  22. Frontiers in Microbiology (IF 6.064)
  23. Frontiers in Physiology (IF 4.755)
  24. Frontiers in Neuroscience (IF 5.152)
  25. Frontiers In Molecular Neuroscience (IF 6.261)
  26. Frontiers in Cellular Neuroscience (IF 6.147)
  27. Frontiers in Cell and Developmental Biology (IF 6.081)
  28. Frontiers in Pediatrics (IF 3.569)
  29. Frontiers in Bioscience-Landmark (IF 3.009)
  30. Biomass Conversion and Biorefinery (Springer, IF=4.05)
  31. Biomedicines (MDPI, IF 4.757)
  32. Cells (MDPI, IF 7.666)
  33. International Journal of Molecular Sciences (MDPI, IF 6.208)
  34. Metabolites (MDPI, IF 5.581)
  35. Molecules (MDPI, IF 4.927)
  36. Membranes (MDPI, IF 4.562)
  37. Toxics (MDPI, IF 4.472)
  38. Marine Drugs (MDPI, IF 6.085)
  39. Antioxidants (MDPI, IF 7.675)
  40. Medicina (MDPI) (IF 2.948)
  41. Pharmaceuticals (MDPI, IF 5.677)
  42. Cancers (MDPI, IF 5.2)
  43. Chemosensors (MDPI, IF 4.2)
  44. Current Issues in Molecular Biology (MDPI, IF 2.976)
  45. Journal of Personalized Medicine (MDPI, IF 3.4)
  46. Foods (MDPI, IF 5.2)
  47. Symmetry (MDPI, IF 2.7)
  48. Crystals (MDPI, IF 2.7)
  49. International Journal of Oncology (IF 5.2)
  50. Journal of Cellular Physiology (IF 6.513)
  51. Microbiological Research (IF 5.070)
  52. Journal of Cancer (IF 4.478)
  53. Asian Journal of Pharmaceutical Sciences (Elsevier, IF 10.2)
  54. European Journal of Pharmacology (Elsevier, IF 5.0)
  55. Brain Research (Elsevier, IF 2.9)
  56. Experimental Cell Research (Elsevier, IF 4.145)
  57. Enzyme and Microbial Technology (Elsevier, IF 3.705)
  58. Journal of Biotechnology (Elsevier, IF 3.595)
  59. Biomedical and Environmental Sciences (Elsevier, IF 3.5)
  60. Molecular Pharmacology (IF 4.054)
  61. Applied Microbiology and Biotechnology (Springer, IF 5.560)
  62. Neural Regeneration Research (IF 6.058)
  63. Marine Biotechnology (Springer, IF 3.727)
  64. Preparative Biochemistry and Biotechnology (IF 3.141)
  65. Canadian Journal of Microbiology (Springer, IF 3.226)
  66. ACS Omega (Elsevier, IF 4.132)
  67. ACS Chemical Neuroscience (Elsevier, IF 5.0)
  68. Process Biochemistry (Elsevier, IF 4.78)
  69. Epilepsy Research (Elsevier, IF 3)
  70. Molecular Pain (IF 3.370)
  71. Acta Histochemica (Elsevier, IF 2.479)
  72. Journal of International Medical Research (IF 1.671)
  73. Expert Opinion on Orphan Drugs (IF 1.041)
  74. Drug Design, Development and Therapy (IF 4.319)
  75. Biomass Conversion and Biorefinery (IF 4.0)
  76. Neurodegenerative Disease Management (IF 2.6)
  77. Journal of Central Nervous System Disease (IF 4.8)
  78. Ecotoxicology and Environmental Safety (IF 6.8)
  79. Life Sciences (IF 6.1)
  80. Neuroscience (Elsevier, IF 3.3)
  81. Oncology Reports (Elsevier, IF 3.9)
  82. Brain-X (Wiley)
  83. Gene Expression
  84. Current Signal Transduction Therapy
  85. Journal of Exploratory Research in Pharmacology
  86. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management (Elsevier)
  87. Journal of Pediatric Neurology
  88. Data in Brief (Elsevier)
  89. Current Signal Transduction Therapy

Conferences and invited presentations

Invited or Keynote Speaker, 

  1. European Section of the American Oil Chemists Society (EAOCS) Annual Meeting & Expo, May 16-19, 2010, Phoenix, Arizona, USA 
  2. 101st American Oil Chemist’s Society (AOCS) Annual Meeting & Expo, May 16-19, 2010, Phoenix, Arizona, USA
  3. LRRK2: Function and Dysfunction - Biochemical Society, March 28-30, 2012, London, UK 
  4. UK Parkinson's Disease Consortium - Scientific advisory meeting, April 4, 2012, London, UK 
  5. Scottish Neuroscience Group, August 31, 2012, Dundee, UK 
  6. Parkinson’s UK research conference, November 5-6, 2012, York, UK 
  7. ASBMB Annual Meeting, San Diego Convention Center, April 26-30, 2014
  8. 3rd Cross-strait and World Chinese Microbial Ecology Summit, May 19-21, 2017, Xiamen, China
  9. Cell Symposia, Aging and Metabolism September 23-25, 2018, Sitges, Spain
  10. Precision Medicine and Ion Channel Retreat (PMICR), November 14-16, 2018, Foshan, China. (Section Chair)
  11. 23rd International Conference on Neurology & Neurophysiology, March 18-19, 2019, Edinburgh, Scotland. (Section Chair)
  12. Southwest Stroke Conference 2019. Friday, 13th September at the University of Exeter.
  13. 6th International Conference on Epilepsy & Treatment” held during September 21-22, 2020, 
  14. 2nd International E-Conference on Pharmacology and Toxicology “Pharmacology Virtual 2021”,December 06-07, 2021 
  15. Cognitive and Behavioral Neurosciences (Virtual Cognitive Neurosciences-2022) on Feb 23-24, 2022
  16. Global Congress on Pharmaceutical Sciences and Clinical Research (PSCR 2022), July 20-22, 2022, Osaka, Japan
  17. Pharmaceutical and Medicinal Chemistry (PMC2022), November 14-16, 2022 Chicago, USA

Organizing Committee Member (and/or invited Speaker) for following international conferences,

  1. International Webinar on Pharmacy and Pharma Networks April 18-19, 2022
  2. International Alzheimer’s Disease & Dementia Conference (Dementia 2022), June 15-16, 2022, Rome, Italy 
  3. Global Meet on Pharmaceutics and Drug Delivery Systems (GMPDDS2022), November 07-09, 2022 in Barcelona, Spain.
  4. Global Summit on Pharmaceutical and Medicinal Chemistry (PMC2022), November 14-16, 2022 in Chicago, USA.
  5. 6th European Congress on Neurology and Brain Disorders, November 17-18, 2022, Rome, Italy.
  6. International Meet on Pharmaceutics and Drug Delivery Systems (PHARMAMEET2023), February 09-11, 2023 in Porto, Portugal.
  7. Neurology and Brain Disorders (Neurology Conference 2023), March 23-24, 2023 at Paris, France.
  8. International Summit on Toxicology and Applied Pharmacology (ISTAP2023), April 27-29, 2023, Valencia, Spain.
  9. International Summit on Pharmaceutics and Drug Delivery Systems (ISPDD2023), May 11-13, 2023 in Brussels, Belgium.
  10. 2ND International Meet on Medicinal Chemistry, Drug Discovery & Drug Delivery (MEDCHEMMEET2023), June 08-10, 2023, at Paris, France.
  11. Global Summit on Pharmaceutical and Medicinal Chemistry (PMC2023), September 21-23, 2023, Lisbon, Portugal during 
  12. Global Summit and Expo on Biotechnology and Bioscience (GSEBB2023), October 23-25, 2023, Barcelona, Spain 
  13. International Forum on Medicinal Chemistry Drug Discovery & Drug Delivery (MCCDFORUM2024), March 07-09, 2024, Florence, Italy

International recognition, such as international research collaborations, visiting research posts in overseas institutions, involvement at senior levels in international research associations, acting as referee for national and international research councils.

2019-  Visiting Professor, Xiamen University, China

2019-  Visiting Professor, Qingdao University, China

2019- Visiting Scholar, Carl von Ossietzky University Oldenburg, Germany

2016-  Visiting Scholar, Institut de Neurobiologie de la Méditerranée (INMed), Marseille, France

2015-2022 Visiting Scholar, Yale University School of Medicine, USA 

Invited lectures

Aix-Marseille Université, Marseille, France 2015

Xiamen University, China 2015

Nankai University, China 2016

Newcastle University, UK 2017

University of Exeter, UK 2017

Xiamen University, China 2018

Nanjing University, China 2019

Xi'an Jiaotong University, China 2019

Fudan Univerisity, China 2020

Shanghai institute of Organic Chemistry,CAS, 2021

Journal and book series Editorships and Editorial board membership

As senior member of the editorial board, setting journal’s scope and direction, organize review processes for submitted manuscripts, including identifying and inviting qualified reviewers, analyzing reviewers’ critiques, comments, and overall scores to make final fair justifications, setting criteria for acceptance, rejection, and revision.  Completion editorial activities for more than 150 manuscripts.

  1. Editorial Board, Medicinal Research Reviews (IF= 13.3)
  2. Associate Editor, Frontiers in Pharmacology (IF=5.988)
  3. Associate Editor, Frontiers in Microbiology (IF=6.064)
  4. Associate Editor, Frontiers in Physiology (IF=4.755)
  5. Editor in Chief, Journal of Modern Biology and Drug Discovery
  6. Executive Editor: Journal of Applied Pharmacy
  7. Section Editor, Current Signal Transduction Therapy
  8. Associate Editor, Exploration of Neuroscience
  9. Topic Editor, Frontiers in Microbiology (IF=6.064) (from 2024) on “Exploration of Marine Microorganisms for Sustainable Biotechnology
  10. Topic Editor, International Journal of Molecular Sciences (IF=6.208) (from 2024) on " Therapeutic Potential: Exploring Membrane Transporters and Channels as Drug Targets"
  11. Topic Editor, Frontiers in Pharmacology (IF=5.988) (from 2023) on “Reviews In Pharmacology of Ion Channels and Channelopathies: 2023
  12. Topic Editor,  Frontiers in Physiology (IF=4.755) (from 2023) on “The Role of Cellular Membrane in Cancer
  13. Topic Editor, Exploration of Neuroscience (from 2023) on “Epilepsy
  14. Topic Editor,  Frontiers in Physiology (IF=4.755) (from 2022) on “Ion Channels and Transporters in Endocrine Cells”
  15. Topic Editor, International Journal of Molecular Sciences (IF=6.208) (from 2022-2023) on "The Roles of Ion Channels and Transporters in Intracellular Signaling"
  16. Topic Editor, Brain Sciences (IF=3.333 (from 2022) on Selected Papers from the " 6th European Congress on Neurology and Brain Disorders” (
  17. Topic Editor, Frontiers in Physiology (IF=4.755) (from 2021) on “Chloride Homeostasis in Animal Cell Physiology”
  18. Topic Editor, Frontiers in Microbiology (IF=6.064) (from 2021) on “Marine Microbial-Derived Molecules and Their Potential Medical and Cosmetic Applications, Volume II”
  19. Topic Editor, Frontiers in Pharmacology (IF=5.988) (from 2022-2023) on “Targeting Pumps, Channels and Transporters for the Treatments of Vascular, Cardiovascular and Kidney Diseases”
  20. Topic Editor, Journal of Visualized Experiments (JoVE)  (IF=1.424) (from 2021-2022) on “ Current Methods in Studying the Functions and Activities of the SLC12 Family of Cation-Chloride-Cotransporters”
  21. Topic Editor, Frontiers in Bioscience-Elite (from 2022) on “Antimicrobial Resistance”
  22. Topic Editor, ASN Neuro (IF=5.20) (from 2020) on “Targeting Ion Channels and Transporters as New Strategies of Treatments for Brain Disorders”
  23. Topic Editor, Processes (IF=3.352) (from 2020-2022)  on “Regulation and Control of Intracellular Signalling”
  24. Topic Editor, Journal of Modern Biology and Drug Discovery (from 2022) on “COVID-19 Therapies and Vaccine Development”
  25. Topic Editor, Frontiers in Pharmacology (IF=5.988) (from 2021-2022) on “Role of Ion Channels in Pain”
  26. Topic Editor, Frontiers in Microbiology (IF=6.064) (2019-2021) on “Marine Microbial-Derived Molecules and Their Potential Medical and Cosmetic Applications, Volume I”
  27. Topic Editor, BioMed Research International (IF=3.246)

Research funding

Previous reserach has been supported by BBSRC, MRC UK and Wellcome Trust, The Michael J Fox Foundation, SIMONS FOUNDATION USA etc..

Current research is supported by the NIH R01, The Royal Society UK, NSFC, Alzheimer's Research UK and Commonwealth Commission Funding etc..

I have Completed review reports for more than 28 applications since 2018.

2018-    Invited as an ad hoc Academic Adviser by reviewing applications for Medical Research Council (MRC) grant

2018-   Invited as an ad hoc Academic Adviser by reviewing applications for UK Biotechnology and Biological Sciences Research Council (BBSRC) grant

2020-      Invited as an ad hoc Academic Adviser by reviewing applications for Austrian Science Fund (FWF), Austria’s central funding body for basic research

2021-      Invited as an ad hoc Academic Adviser by reviewing applications for Carnegie Trust for the Universities of Scotland

2021-      Invited as an ad hoc Academic Adviser by reviewing applications for the Commonwealth Scholarship Commission (CSC).

2022-   Invited as an ad hoc Academic Adviser and panel member for the MRC Impact Acceleration Account (IAA)

2024-  Invited as an ad hoc Academic Adviser by reviewing applications for the British Heart Foundation (BHF).

Back to top


I have enjoyed varied and extensive teaching responsibilities, which covered the following areas:

  • Biochemistry, Signalling Transduction, Drug Discovery
  • Biological techniques and scientific practice to undergraduate students
  • Assessment and marking of coursework and exams

I contribute to the following undergraduate modules 

Anatomy and Physiology (PAM1011)

Integrated Human Physiology (CSC1005)

Translational Medical Science (CSC4019)

Fundamental Skills for Medical Scientists (CSC1004)

Academic and Professional Support (CSC1905)

Chemistry of Life (CSC1009)

Anatomical Sciences (CSC2009)

Academic tutor for BMBS year 1, 2 and 3

Dissertation supervisor for  CSC4020, CSC3028 and CSC3029

Rational Drug Design (CSC4006, CSC3010)



Back to top

Supervision / Group

Postgraduate researchers

  • Sunday Josiah
  • Nur Farah Meor Azlan


  • Katie Andrews (Project student since 2019)
  • Mr A. Brown (Research student since 2019)
  • Miss C. Davis (Research student since 2018)
  • Dr F. Donneger (Visiting Scholar from INSERM-Sorbonne Université since 2019)
  • Mr A. Haley (A2I funded research student from 2017)
  • Mr J. Y. Lee (Research student from 2018)
  • Prof. Pei-Feng Li (Visiting Professor from College of Medicine, University of Qingdao, China since 2019)
  • Mr Shihan Salihu Project student since 2020
  • Mr Tom Seymour Project student since 2020
  • Mr G. Stewart (A2I funded research student since 2017)
  • Mr L. Tillman (Research student since 2018)
  • Dr. Z. Wu (Senior Visiting Scholar from Newcastle University UK since 2017)

Back to top

Edit Profile